(Q37710786)

22 August 2017

1 reference

title

Treating irritable bowel syndrome with probiotics: the evidence (English)

1 reference

22 August 2017

0 references

irritable bowel syndrome

1 reference

2

J D Sanderson

1 reference

22 August 2017

G C Parkes

1

1 reference

22 August 2017

K Whelan

series ordinal

3

1 reference

22 August 2017

publication date

18 March 2010

1 reference

Proceedings of the Nutrition Society

22 August 2017

published in

1 reference

22 August 2017

volume

69

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

187-194

1 reference

Lactulose breath testing, bacterial overgrowth, and IBS: just a lot of hot air?

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Intestinal microecology and quality of life in irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Towards positive diagnosis of the irritable bowel

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Applied principles of neurogastroenterology: physiology/motility sensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

A mixture ofEscherichia coli(DSM 17252) andEnterococcus faecalis(DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Meta-analysis of probiotics for the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Bacterial probiotic modulation of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

Probiotics for prevention of necrotizing enterocolitis in preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Small intestinal bacterial overgrowth and the irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Activation of the mucosal immune system in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children.

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria.

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Tegaserod for the treatment of irritable bowel syndrome and chronic constipation

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Increased mast cells in the irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Functional bowel disorders and functional abdominal pain

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Terminal ileal mucosal mast cells in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Re: Pimentel et al.--Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS002966511000011X

7 January 2021

10.1017/S002966511000011X

Identifiers

DOI

1 reference

22 August 2017

1 reference